Inhibitor Therapeutics Net Income
| INTI Stock | USD 0.08 0.02 32.20% |
As of the 2nd of February, Inhibitor Therapeutics retains the Risk Adjusted Performance of 0.0834, downside deviation of 11.1, and Market Risk Adjusted Performance of (0.64). Inhibitor Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Inhibitor Therapeutics, which can be compared to its competitors.
Inhibitor Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Inhibitor Therapeutics' valuation are provided below:Inhibitor Therapeutics does not presently have any fundamental trends for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Inhibitor |
Inhibitor Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Inhibitor Therapeutics' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Inhibitor Therapeutics.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Inhibitor Therapeutics on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Inhibitor Therapeutics or generate 0.0% return on investment in Inhibitor Therapeutics over 90 days. Inhibitor Therapeutics is related to or competes with Devonian Health. Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patient... More
Inhibitor Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Inhibitor Therapeutics' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Inhibitor Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 11.1 | |||
| Information Ratio | 0.099 | |||
| Maximum Drawdown | 107.08 | |||
| Value At Risk | (12.12) | |||
| Potential Upside | 14.29 |
Inhibitor Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inhibitor Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Inhibitor Therapeutics' standard deviation. In reality, there are many statistical measures that can use Inhibitor Therapeutics historical prices to predict the future Inhibitor Therapeutics' volatility.| Risk Adjusted Performance | 0.0834 | |||
| Jensen Alpha | 1.49 | |||
| Total Risk Alpha | 0.7427 | |||
| Sortino Ratio | 0.1246 | |||
| Treynor Ratio | (0.65) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Inhibitor Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Inhibitor Therapeutics February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0834 | |||
| Market Risk Adjusted Performance | (0.64) | |||
| Mean Deviation | 6.82 | |||
| Semi Deviation | 6.16 | |||
| Downside Deviation | 11.1 | |||
| Coefficient Of Variation | 978.45 | |||
| Standard Deviation | 13.97 | |||
| Variance | 195.11 | |||
| Information Ratio | 0.099 | |||
| Jensen Alpha | 1.49 | |||
| Total Risk Alpha | 0.7427 | |||
| Sortino Ratio | 0.1246 | |||
| Treynor Ratio | (0.65) | |||
| Maximum Drawdown | 107.08 | |||
| Value At Risk | (12.12) | |||
| Potential Upside | 14.29 | |||
| Downside Variance | 123.21 | |||
| Semi Variance | 38.0 | |||
| Expected Short fall | (15.49) | |||
| Skewness | 3.67 | |||
| Kurtosis | 19.37 |
Inhibitor Therapeutics Backtested Returns
Inhibitor Therapeutics is out of control given 3 months investment horizon. Inhibitor Therapeutics holds Efficiency (Sharpe) Ratio of 0.0953, which attests that the entity had a 0.0953 % return per unit of risk over the last 3 months. We were able to interpolate and analyze data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.38% are justified by taking the suggested risk. Use Inhibitor Therapeutics Downside Deviation of 11.1, risk adjusted performance of 0.0834, and Market Risk Adjusted Performance of (0.64) to evaluate company specific risk that cannot be diversified away. Inhibitor Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -2.19, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Inhibitor Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Inhibitor Therapeutics is expected to outperform it. Use Inhibitor Therapeutics total risk alpha and the relationship between the potential upside and price action indicator , to analyze future returns on Inhibitor Therapeutics.
Auto-correlation | -0.18 |
Insignificant reverse predictability
Inhibitor Therapeutics has insignificant reverse predictability. Overlapping area represents the amount of predictability between Inhibitor Therapeutics time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Inhibitor Therapeutics price movement. The serial correlation of -0.18 indicates that over 18.0% of current Inhibitor Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.18 | |
| Spearman Rank Test | -0.02 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Inhibitor Therapeutics reported net income of (298,632). This is 100.09% lower than that of the Healthcare sector and 100.43% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.05% higher than that of the company.
Inhibitor Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inhibitor Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Inhibitor Therapeutics could also be used in its relative valuation, which is a method of valuing Inhibitor Therapeutics by comparing valuation metrics of similar companies.Inhibitor Therapeutics is currently under evaluation in net income category among its peers.
Inhibitor Fundamentals
| Return On Asset | -2.11 | |||
| Current Valuation | 26.98 M | |||
| Shares Outstanding | 376.86 M | |||
| Shares Owned By Insiders | 79.33 % | |||
| Number Of Shares Shorted | 19.88 K | |||
| Price To Earning | (4.67) X | |||
| Price To Book | 76.91 X | |||
| EBITDA | (283.8 K) | |||
| Net Income | (298.63 K) | |||
| Cash And Equivalents | 24.95 K | |||
| Total Debt | 331 K | |||
| Debt To Equity | 11.81 % | |||
| Current Ratio | 0.04 X | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (220.43 K) | |||
| Short Ratio | 0.07 X | |||
| Earnings Per Share | (0) X | |||
| Beta | -0.46 | |||
| Market Capitalization | 22.99 M | |||
| Total Asset | 58.78 K | |||
| Retained Earnings | (60.33 M) | |||
| Working Capital | 1.65 M | |||
| Current Asset | 2.39 M | |||
| Current Liabilities | 736.4 K | |||
| Net Asset | 58.78 K |
About Inhibitor Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inhibitor Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibitor Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibitor Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VGIAX | Vanguard Growth And | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| ASML | ASML Holding NV |
Other Information on Investing in Inhibitor OTC Stock
Inhibitor Therapeutics financial ratios help investors to determine whether Inhibitor OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Inhibitor with respect to the benefits of owning Inhibitor Therapeutics security.